AI Article Synopsis
- Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by the constriction and dilation of cerebral blood vessels, but its underlying causes are not fully understood.
- Two cases of RCVS linked to the drug teprotumumab were reported, involving two women with Graves' eye disease who experienced symptoms like leg weakness and severe headaches after starting the medication.
- Both patients showed improvement after treatment with verapamil, leading to concerns about the potential role of teprotumumab in triggering RCVS, warranting further research into this connection.
Article Abstract
Background: Reversible Cerebral Vasoconstriction Syndrome (RCVS) involves cerebral vasculature constriction and dilation. While the exact pathophysiology of RCVS is still not fully understood, there are multiple etiological factors suggested to be implicated in triggering RCVS. We report two RCVS cases potentially linked to teprotumumab. Case 1: A 59-year-old female with Graves' eye disease (GED) developed leg weakness and headache after initiating teprotumumab, and neuroimaging studies revealed multifocal cerebral vasospasm (CVS). Verapamil mitigated vasospasm and the patient overall improved. Case 2: A 71-year-old female with GED developed thunderclap headache two months after starting teprotumumab, with subarachnoid hemorrhage (SAH) and CVS revealed on neuroimaging studies. The patient improved on verapamil and was discharged without deficits.
Conclusions: The temporal correlation between teprotumumab initiation and RCVS's symptom onset raises concern for the potential involvement of teprotumumab in triggering RCVS via disrupting cerebrovascular modulation. Further research is needed to investigate this proposed association.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304978 | PMC |
| http://dx.doi.org/10.1093/omcr/omae085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term effects of linear versus macrocyclic GBCAs on gene expression in the central nervous system of mice.
Eur Radiol Exp
January 2025
Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Background: We examined chronic gadolinium retention impact on gene expression in the mouse central nervous system (CNS) after injection of linear or macrocyclic gadolinium-based contrast agents (GBCAs).
Methods: From 05/2022 to 07/2023, 36 female mice underwent weekly intraperitoneal injections of gadodiamide (2.5 mmol/kg, linear), gadobutrol (2.
Edaravone Improves Motor Dysfunction Following Brachial Plexus Avulsion Injury in Rats.
ACS Chem Neurosci
January 2025
Department of Neurology, Multi-Omics Research Center for Brain Disorders,The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
Brachial plexus root avulsion (BPRA) is often caused by road collisions, leading to total loss of motor function in the upper limb. At present, effective treatment options remain limited. Edaravone (EDA), a substance that eliminates free radicals, exhibits numerous biological properties, including neuroprotective, antioxidant and anti-inflammatory effects.
View Article and Find Full Text PDFPostpartum Hellp Syndrome Associated With Posterior Reversible Encephalopathy Syndrome.
Eur J Case Rep Intern Med
December 2024
Critical Care, Intensive Care Unit, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
Unlabelled: Haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome is a poorly understood, life-threatening multisystemic condition related to pregnancy with a rapid onset, typically observed in patients with severe pre-eclampsia. Various mechanisms may lead to diffuse endothelial damage associated with HELLP and possible brain involvement. A comprehensive review of PubMed, Embase and Cochrane databases was conducted to examine the clinical, laboratory and radiological features associated with postpartum HELLP syndrome, particularly its potential association with posterior reversible encephalopathy syndrome (PRES).
View Article and Find Full Text PDFAENK ameliorates cognitive impairment and prevents Tau hyperphosphorylation through inhibiting AEP-mediated cleavage of SET in rats with ischemic stroke.
J Neurochem
January 2025
Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Brain damage induced by ischemia promotes the development of cognitive dysfunction, thus increasing the risk of dementia such as Alzheimer's disease (AD). Studies indicate that cellular acidification-triggered activation of asparagine endopeptidase (AEP) plays a key role in ischemic brain injury, through multiple molecular pathways, including cleavage of its substrates such as SET (inhibitor 2 of PP2A, I ) and Tau. However, whether direct targeting AEP can effectively prevent post-stroke cognitive impairment (PSCI) remains unanswered.
View Article and Find Full Text PDFClinical characteristics and repositioning efficacy analysis of posterior canal-benign paroxysmal positional vertigo-canalolithiasis and vertigo-cupulolithiasis patients.
Acta Otolaryngol
January 2025
Department of Neurology, the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Currently, there is a paucity of research comparing the clinical characteristics and repositioning efficacy between posterior canal-benign paroxysmal positional vertigo-canalolithiasis (PC-BPPV-ca) and posterior canal-benign paroxysmal positional vertigo-cupulolithiasis (PC-BPPV-cu).
Aims/objectives: To observe the clinical characteristics and compare the efficacy of repositioning maneuvers between PC-BPPV-ca and PC-BPPV-cu patients.
Material And Methods: Clinical information of patients was collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!